Home
/
Pharma-Bio Serv, Inc.
/
Financials
/
Quarterly
Pharma-Bio Serv, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Pharma-Bio Serv, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Jan 31, 2026
$2.29M
Mar 17, 2026
Q3
2025
Jul 31, 2025
$1.96M
Sep 15, 2025
Q2
2025
Apr 30, 2025
$2.42M
Jun 16, 2025
Q1
2026
Jan 31, 2025
$2.47M
Mar 17, 2026
Q3
2025
Jul 31, 2024
$2.42M
Sep 15, 2025
Q2
2025
Apr 30, 2024
$2.38M
Jun 16, 2025
Q1
2025
Jan 31, 2024
$2.38M
Mar 17, 2025
Q3
2024
Jul 31, 2023
$4.58M
Sep 16, 2024
Q2
2024
Apr 30, 2023
$4.56M
Jun 14, 2024
Q1
2024
Jan 31, 2023
$4.24M
Mar 18, 2024
Q3
2023
Jul 31, 2022
$4.77M
Sep 14, 2023
Q2
2023
Apr 30, 2022
$4.97M
Jun 14, 2023
Q1
2023
Jan 31, 2022
$5.02M
Mar 17, 2023
Q3
2022
Jul 31, 2021
$4.99M
Sep 14, 2022
Q2
2022
Apr 30, 2021
$5.04M
Jun 14, 2022
Q1
2022
Jan 31, 2021
$4.49M
Mar 17, 2022
Q3
2021
Jul 31, 2020
$6.28M
Sep 14, 2021
Q2
2021
Apr 30, 2020
$5.65M
Jun 14, 2021
Q1
2021
Jan 31, 2020
$4.61M
Mar 17, 2021
Q3
2020
Jul 31, 2019
$4.97M
Sep 14, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Jan 31, 2026
$32.9K
Mar 17, 2026
Q3
2025
Jul 31, 2025
($204.3K)
Sep 15, 2025
Q2
2025
Apr 30, 2025
$95.4K
Jun 16, 2025
Q1
2026
Jan 31, 2025
$8.5K
Mar 17, 2026
Q3
2025
Jul 31, 2024
($309.2K)
Sep 15, 2025
Q2
2025
Apr 30, 2024
($213.8K)
Jun 16, 2025
Q1
2025
Jan 31, 2024
($270.7K)
Mar 17, 2025
Q3
2024
Jul 31, 2023
$526.2K
Sep 16, 2024
Q2
2024
Apr 30, 2023
$404.7K
Jun 14, 2024
Q1
2024
Jan 31, 2023
$426.4K
Mar 18, 2024
Q3
2023
Jul 31, 2022
$288.0K
Sep 14, 2023
Q2
2023
Apr 30, 2022
$240.0K
Jun 14, 2023
Q1
2023
Jan 31, 2022
$305.2K
Mar 17, 2023
Q3
2022
Jul 31, 2021
$2.28M
Sep 14, 2022
Q2
2022
Apr 30, 2021
$240.3K
Jun 14, 2022
Q3
2021
Apr 30, 2021
$240.3K
Sep 14, 2021
Q1
2022
Jan 31, 2021
$268.0K
Mar 17, 2022
Q3
2021
Jan 31, 2021
$268.0K
Sep 14, 2021
Q2
2021
Jan 31, 2021
$268.0K
Jun 14, 2021
Q3
2021
Jul 31, 2020
$692.1K
Sep 14, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Jan 31, 2026
($94.5K)
Mar 17, 2026
Q3
2025
Jul 31, 2025
($313.9K)
Sep 15, 2025
Q2
2025
Apr 30, 2025
($98.3K)
Jun 16, 2025
Q1
2026
Jan 31, 2025
($92.2K)
Mar 17, 2026
Q3
2025
Jul 31, 2024
($381.8K)
Sep 15, 2025
Q2
2025
Apr 30, 2024
($313.4K)
Jun 16, 2025
Q1
2025
Jan 31, 2024
($438.3K)
Mar 17, 2025
Q3
2024
Jul 31, 2023
$460.5K
Sep 16, 2024
Q2
2024
Apr 30, 2023
$380.1K
Jun 14, 2024
Q1
2024
Jan 31, 2023
$328.6K
Mar 18, 2024
Q3
2023
Jul 31, 2022
$369.5K
Sep 14, 2023
Q2
2023
Apr 30, 2022
$280.6K
Jun 14, 2023
Q1
2023
Jan 31, 2022
$355.8K
Mar 17, 2023
Q3
2022
Jul 31, 2021
$360.5K
Sep 14, 2022
Q2
2022
Apr 30, 2021
$264.8K
Jun 14, 2022
Q1
2022
Jan 31, 2021
$319.1K
Mar 17, 2022
Q3
2021
Jul 31, 2020
$816.7K
Sep 14, 2021
Q2
2021
Apr 30, 2020
$720.4K
Jun 14, 2021
Q1
2021
Jan 31, 2020
$536.8K
Mar 17, 2021
Q3
2020
Jul 31, 2019
$360.7K
Sep 14, 2020